文献速递肿瘤 PET/CT核素与放射性配体治疗

99mTc-FAPI SPECT/CT 在前列腺癌初始分期中优于 99mTc-PSMA 显像:一例病例报告

Superior Performance of 99m Tc-FAPI SPECT/CT Compared With 99m Tc-PSMA Scintigraphy in the Initial Staging of Prostate Cancer: A Case Report.
PubMed 文献 · Clin Nucl Med · 2025-06-04

本文报告一例 62 岁男性腺泡型前列腺腺癌患者,初始分期行 99mTc-PSMA 显像,因转移灶 PSMA 亲和力低,进一步行 99mTc-FAPI-46 显像以改善转移灶检出并为 FAP 靶向放射性配体治疗提供可能。本例中 99mTc-FAPI-46 诊断性能优于 99mTc-PSMA 显像,提示其可用于肿瘤 PSMA 低表达或怀疑肿瘤异质性的情形。

要点

  • 62 岁男性腺泡型前列腺腺癌,初始分期先行 99mTc-PSMA 显像。
  • 因转移灶 PSMA 亲和力低,加做 99mTc-FAPI-46 显像以改善转移检出。
  • 本例中 99mTc-FAPI-46 诊断性能优于 99mTc-PSMA 显像。

核心结论

  • 本例中 99mTc-FAPI-46 诊断性能优于 99mTc-PSMA 显像,提示其可用于肿瘤 PSMA 低表达或怀疑肿瘤异质性的情形。

研究设计与样本

  • 病例报告:一例 62 岁男性腺泡型前列腺腺癌患者,初始分期行 99mTc-PSMA 显像。

主要发现

  • 99mTc-PSMA 显像显示转移灶 PSMA 亲和力低。
  • 因转移灶 PSMA 亲和力低,进一步行 99mTc-FAPI-46 显像以改善转移灶检出并为 FAP 靶向放射性配体治疗提供可能。
  • 本例中 99mTc-FAPI-46 诊断性能优于 99mTc-PSMA 显像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a case involving a 62-year-old man diagnosed with acinar-type prostate adenocarcinoma, who was referred for initial staging with 99m Tc-PSMA scintigraphy. Considering the metastatic lesions exhibited low PSMA avidity, a 99m Tc-FAPI-46 scintigraphy was conducted to improve the detection of metastases and to potentially facilitate future radio-ligand therapy using FAP-targeted radiopharmaceuticals. In this experience, 99m Tc-FAPI-46 demonstrated superior diagnostic performance compared with 99m Tc-PSMA scintigraphy, underscoring its potential utility in cases where tumors exhibit low PSMA expression or when tumor heterogeneity is suspected.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Saber Tanha A, Raeisi N, Jafari Zarrin Ghabaei F, et al. Superior Performance of 99m Tc-FAPI SPECT/CT Compared With 99m Tc-PSMA Scintigraphy in the Initial Staging of Prostate Cancer: A Case Report. Clin Nucl Med. 2025. PMID: 40472264. doi:10.1097/RLU.0000000000006005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。